Skip to main content

Fong James K's Form 4 filing

Cti Biopharma Corp (CTIC) · filed Jan 26, 2023

Accession no.
0000891293-23-000003
Filed
Jan 26, 2023
Trade date
Feb 19, 2019-Jan 24, 2023
Filing delay
1,437 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market sales total $600.0K. It was filed 1437 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Fong James KCIK 0001916577Officer (EVP & Chief Commercial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 24, 2023common stockMOption exerciseAcquired+100,000$0.95+$95,000103,565Direct
Jan 24, 2023common stockSSaleDisposed−100,000$6.00−$600,0003,565Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 19, 2019Common StockAGrant or awardAcquired+288,000$0.00$0288,000Direct
Jan 24, 2023Common StockMOption exerciseDisposed−100,000$0.00$0188,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)